Bio-outsourcing

What’s holding up biosimilars in the US? Researchers investigate

What’s holding up biosimilars in the US? Researchers investigate

By Zachary Brennan

Politics might not be the only obstacle in getting biosimilars approved in the US, though much of the rest of the world seems intent on obtaining approvals as fast as possible, according to a new report from research company Frost & Sullivan.

Repligen expands facilities in Massachusetts to meet customer demand

Repligen ups disposable chromatography column capacity

By Zachary Brennan

US biopharma company Repligen has completed a 9,000 square foot expansion of its facilities in Massachusetts to meet growing customer demand for disposable chromatography columns and warehousing.

Neutrophils: Stada and Apotex to enter crowded EU filgrastim  market

update

Stada to sell Apotex' biosimilar filgrastim in Europe

By Gareth Macdonald

Stada Arzneimittel has licensed European rights to a biosimilar version of the white blood cell booster filgrastim from Apotex and says it is not worried by competitors already in the market.

Follow us

Product Innovations